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Introduction {#sec1}
============

Upon viral infection, activation of the innate immune response mobilizes an antiviral state. Central to this process is the production of type 1 interferons (IFNs); these cytokines induce the expression of a cascade of IFN-stimulated genes (ISGs), many of which have direct antiviral properties ([@bib16], [@bib5]). As with many viruses, HIV type-1 (HIV-1) replication is suppressed by the IFN response (reviewed by [@bib16]). In recent years, human myxovirus resistance 2 (MX2; also called MXB) has been identified as a potent, IFN-induced inhibitor of HIV-1 infection ([@bib24], [@bib29], [@bib33], [@bib8], [@bib15]) and herpesvirus infection, including herpes simplex viruses 1 (HSV-1) and 2 (HSV-2) ([@bib11], [@bib41], [@bib44]). MX2 mediates a block to HIV-1 infection after reverse transcription (the synthesis of viral cDNA), but prior or together with the integration of viral DNA into host chromosomal DNA ([@bib24], [@bib29], [@bib33], [@bib34]).

Early studies showed that the HIV-1 Capsid (CA) protein is the virus-encoded determinant of MX2 sensitivity, since point mutations in CA can yield MX2-insensitive viruses ([@bib24], [@bib29], [@bib33], [@bib9], [@bib34], [@bib8]). Notably, such mutations may be located on different interfaces of the viral CA, as illustrated by the cyclophilin A (CYPA)-binding loop mutations P90A or G89V, and the hexamer trimeric-interface mutations G208R or T210K, thereby implying a complicated interplay between the CA and MX2. It has also been demonstrated that MX2 and the CA can interact *in vitro* using assemblies of the CA and CA-Nucleocapsid (CANC) as surrogates for the HIV-1 capsid lattice ([@bib19], [@bib20])

Because of the presence of an alternative start codon at position 26, human MX2 is expressed as two different isoforms of 78 and 76 kDa. Early work established that only the full-length form of MX2 is antiviral, while the short isoform has no observable anti-HIV-1 activity ([@bib25], [@bib34]), a feature shared in the inhibition of herpesviruses ([@bib11], [@bib41]). Accordingly, it was proposed that only the long isoform can interact with CA ([@bib20]), with additional studies suggesting a dependence on the arginine residues at positions 11--13 within the amino-terminal domain (NTD) ([@bib20], [@bib42]). Additionally, it has been shown that a chimeric dimer consisting of maltose-binding protein bearing the amino-terminal 35 residues of MX2 binds to CA assemblies, specifically at the CA tri-hexamer interface ([@bib43]). However, earlier work by [@bib19] also showed that a truncated form of MX2 lacking the amino-terminal 84 residues may still interact with CA assemblies, albeit with lower affinity. Another unresolved aspect of MX2's mechanism of action concerns the extent of oligomerization needed for viral inhibition, since some studies have found that MX2 dimerization is sufficient ([@bib7], [@bib14]), whereas another analysis proposed that higher-order oligomers might be important ([@bib2]).

Human MX2 belongs to the dynamin-like GTPase family, which also includes the related protein MX1 (also called MXA). MX1 has been acknowledged as an antiviral ISG for many years (reviewed by [@bib47]) and can act on a broad spectrum of viruses, including influenza A virus (IAV), hepatitis B virus (HBV), Thogoto virus (THOV), or measles virus ([@bib36], [@bib18], [@bib31], [@bib23]), but not HIV-1 ([@bib24], [@bib29], [@bib33]). Like MX1, MX2 is composed of a disordered NTD, followed by a GTPase (G) domain and a stalk (ST) domain, connected by three hinge-like bundle signaling elements (BSEs). While the G and ST domains of MX1 and MX2 are notably similar in sequence and overall structure ([@bib21], [@bib22], [@bib19]), the NTD of MX2 is notably longer than that of MX1 (91 versus 43 amino acids, respectively). There are clear differences in the determinants of viral inhibition between MX1 and MX2: (1) While MX2 prevents the nuclear accumulation of HIV-1 cDNAs, human MX1 is thought to act at a post-transcriptional level by inhibiting the nuclear export of HBV RNAs ([@bib23]) or prior to transcription by trapping THOV nucleocapsids in the cytoplasm ([@bib31]). (2) A disordered loop in the ST domain (called L4) of MX1 is an important determinant of virus inhibition, at least for IAV and THOV, where an interaction with the viral nucleoprotein (NP) has been shown ([@bib35]), but this element is dispensable for MX2-mediated HIV-1 suppression ([@bib25], [@bib48]). (3) For MX2, a key region necessary for the inhibition of HIV-1 has been shown to be the NTD; for example, a chimeric MX1 protein bearing the NTD of MX2 displays equivalent antiviral activity to wild-type MX2 ([@bib25], [@bib26]). (4) While GTPase activity is required for MX1-mediated virus suppression, this enzymatic capability is dispensable for HIV-1 inhibition by MX2 ([@bib35], [@bib24], [@bib29], [@bib34]). However, GTP hydrolysis may be involved in the organization of MX2 oligomerization ([@bib2]), and GTPase activity is required for the inhibition of herpesvirus infections ([@bib11], [@bib41]).

Here, we investigate in depth the requirements for the interaction between MX2 and the HIV-1 capsid. We show that in addition to the previously described NTD binding site, the G domain of MX2 encodes a second, independent capsid-binding site. Importantly, this site not only contributes to the antiviral activity of full-length MX2, but it also enables the short MX2 isoform to act as a negative regulator of the full-length protein.

Results {#sec2}
=======

MX2 Binds Assembled HIV-1 CANC Complexes {#sec2.1}
----------------------------------------

The HIV-1 capsid lattice that forms the distinctive conical core of viral particles is composed of hexameric and pentameric assemblies of the viral CA protein. One well-established experimental model for studying the capsid lattice entails the use of CANC nanotubes that are assembled *in vitro* using purified recombinant protein ([@bib10], [@bib27]). These have been employed extensively for high-resolution structural studies ([@bib3], [@bib13]) and for analyzing interactions between the capsid lattice and cellular proteins ([@bib46], [@bib32], [@bib4], [@bib12], [@bib40]).

It has previously been reported that human MX2 interacts with HIV-1 CANC complexes ([@bib19], [@bib20]). We first confirmed this observation using extracts of transfected 293T cells expressing MX1 or MX2, as well as a known CA-binding protein (cleavage and polyadenylation specificity factor subunit 6 \[CPSF6\]; [@bib39]) and an unrelated negative control protein (green fluorescent protein, GFP), all bearing a FLAG-tag. Cell lysates were incubated with assembled CANC complexes, subjected to centrifugation through a sucrose cushion such that only very-high-molecular-weight CANC complexes together with interacting factors were pelleted, and then analyzed by immunoblotting.

As expected, CPSF6 was readily detected in the pellet fraction when CANC complexes were present, but not when they were absent, and GFP failed to interact with these complexes ([Figure 1](#fig1){ref-type="fig"}A). As previously shown ([@bib20]), MX2 was also able to bind to CANC complexes, while the related MX1 protein was not, again illustrating the specificity of this interaction ([Figure 1](#fig1){ref-type="fig"}A). Further confirmation of this finding was obtained using lysates from IFNα-treated U87-MG CD4/CXCR4 cells, where both the long and short isoforms of endogenous IFNα-induced MX2 were shown to interact with CANC complexes, but endogenous MX1 did not ([Figure 1](#fig1){ref-type="fig"}B) ([@bib20]).Figure 1Binding of MX2 and Chimeric Proteins to HIV-1 CANC Nanotubes(A) 293T cells were transfected with vectors expressing human MX2, human MX1, GFP, or human CPSF6. Cell lysates were then incubated in the presence or absence of *in vitro* assembled CANC complexes and subjected to centrifugation through a sucrose cushion. Resulting supernatant (Sup) and pellet fractions, together with the input sample, were analyzed by immunoblot (n ≥ 20). A representative immunoblot for CANC (α-CA) is shown.(B) CANC complexes were incubated with lysates from U87-MG CD4/CXCR4 cells treated with 500 U/ml of IFNα and pelleted through a sucrose cushion. Input, Sup, and pellet fractions were analyzed by immunoblot (n = 4).(C) Chimeric MX1 or GFP proteins containing the N-terminal domain of MX2 were expressed in 293T cells. Cell lysates were incubated with CANC complexes, pelleted through a sucrose cushion, and input, Sup, and pellet fractions were analyzed by immunoblot. A representative immunoblot for CANC (α-CA) is shown (n = 5).(D) Deletions of residues 1--25 were introduced into MX2, MX1 (NTD~MX2~), or GFP (NTD~MX2~), as well as deletion of residues 1--91 from MX2. 293T cell lysates expressing these proteins were mixed with CANC assemblies, pelleted through a sucrose cushion, and input, Sup, and pellet fractions were analyzed by immunoblot (n ≥ 4). A representative immunoblot for CANC (α-CA) is shown.(E) The triple-arginine mutation R11-13A was introduced into MX2 and GFP (NTD~MX2~). Lysates from transfected 293T cells expressing these proteins were mixed with CANC assemblies, pelleted through a sucrose cushion, and input, Sup, and pellet fractions were analyzed by immunoblot (n = 5). A representative immunoblot for CANC (α-CA) is shown.

The NTD of MX2 Is Not Solely Responsible for the Interaction with the HIV-1 Capsid Lattice {#sec2.2}
------------------------------------------------------------------------------------------

Previous studies have proposed that the NTD of MX2 is entirely responsible for capsid binding ([@bib20], [@bib42]), though other analyses have indicated that this region may not be absolutely required ([@bib19]). To explore the capsid-binding determinants of MX2 in further detail, we determined the CANC binding phenotypes for a series of GFP/MX2 and MX1/MX2 chimeric proteins, as well as MX2 deletion and point mutants. We first transferred the NTD of MX2 to MX1 and GFP, with the resulting chimeric proteins (MX1 \[NTD~MX2~\] and GFP \[NTD~MX2~\]) naturally expressing corresponding long and short isoforms ([Figure 1](#fig1){ref-type="fig"}C) due to the alternative start codon at position 26. As noted before, MX1 carrying the MX2 NTD acquired the ability to bind to CANCs ([@bib20]), an observation recapitulated with the chimeric GFP (NTD~MX2~) protein ([Figure 1](#fig1){ref-type="fig"}C); importantly, only the chimera corresponding to the long isoform of MX2 bound to CANC assemblies, with the chimera corresponding to the short isoform that lacks the amino-terminal 25 residues (GFP \[NTD~MX2~ Δ1-25\]) failing to interact ([Figure 1](#fig1){ref-type="fig"}C).

Next, focusing on the NTD, we found that the deletion of the amino-terminal 25 amino acids from the GFP (NTD~MX2~) and MX1 (NTD~MX2~) chimeric proteins (i.e., proteins that correspond to short isoforms expressed from the downstream codon) abolished the ability of the NTD to interact with CANC complexes ([Figure 1](#fig1){ref-type="fig"}D). Critically, however, we found that the short isoform of MX2 (MX2 Δ1-25) was still able to bind to CANC complexes ([Figure 1](#fig1){ref-type="fig"}D), consistent with previous results using recombinant MX2 that lacked the first 84 residues ([@bib19]). This suggested that MX2 contains capsid-binding determinants that reside beyond the amino-terminal 84 amino acids; this was reinforced by the finding that a truncated form of MX2 lacking the entire NTD (MX2 Δ1-91; hereafter called MX2 ΔNTD) also interacted with CANC complexes ([Figure 1](#fig1){ref-type="fig"}D). Residues 11--13 of the NTD of MX2 have been shown to be important for both viral inhibition ([@bib26]) and CANC complex binding ([@bib42], [@bib43]). While substitution of these three arginines for alanine abrogated the interaction between GFP (NTD~MX2~) and CANC complexes, the effect on the binding of full-length MX2 was modest ([Figure 1](#fig1){ref-type="fig"}E). Taken together, these data confirm the important role played by the triple-arginine motif of the NTD in CA binding and highlight the importance of the additional, independent region(s) of MX2 for interacting with the HIV-1 capsid.

The G Domain of MX2 Interacts with the HIV-1 Capsid {#sec2.3}
---------------------------------------------------

To map the additional region(s) of MX2 that can bind the capsid lattice, we created a library of MX1/MX2 chimeras where different protein domains were swapped and binding to CANC complexes was assessed ([Table 1](#tbl1){ref-type="table"}). One unexpected complication in these experiments was that the NTD of MX1 appeared to have an inhibitory role on the ability of MX2 to bind to CANCs ([Table 1](#tbl1){ref-type="table"}; [Figure 2](#fig2){ref-type="fig"}A). Accordingly, all chimeric proteins where MX1 domains were introduced into MX2 were configured not to contain an NTD. We found that exchanging the MX2 G domain either alone or with the ST domain for corresponding regions of MX1 abrogated CANC complex binding ([Figure 2](#fig2){ref-type="fig"}A). Importantly, a reverse chimera comprising MX1 ΔNTD bearing the G domain of MX2 clearly interacted with CANC assemblies, whereas MX1 ΔNTD did not ([Figure 2](#fig2){ref-type="fig"}B). Finally, by showing that a fusion of the MX2 G domain to GFP, GFP (G~MX2~), also bound to CANCs (albeit relatively modestly), we confirmed that the G domain of MX2 contains a second capsid-binding site ([Figure 2](#fig2){ref-type="fig"}B).Table 1Summary of MX1/MX2 Chimeric Protein Binding to CANC Complexes![](fx2.gif)Figure 2MX2 Is Able to Bind to CANC Complexes through Its G Domain(A) NTD, ST, and/or G domains of MX1 were introduced into the truncated form of MX2 lacking the NTD (MX2 ΔNTD). 293T cell lysates expressing these proteins were mixed with CANC assemblies, pelleted through a sucrose cushion, and input, Sup, and pellet fractions were analyzed by immunoblot (n = 5). A representative immunoblot for CANC (α-CA) is shown.(B) NTD truncated MX1 (MX1 ΔNTD) with or without the G domain of MX2, or a chimeric protein comprising GFP and the G domain of MX2 were expressed in 293T cells. Cell lysates were mixed with CANC assemblies, pelleted through a sucrose cushion, and input, Sup, and pellet fractions were analyzed by immunoblot. A representative immunoblot for CANC (α-CA) is shown (n ≥ 3).

The Short Isoform of MX2 (MX2 Δ1-25) Negatively Regulates Wild-Type MX2 Function {#sec2.4}
--------------------------------------------------------------------------------

Having demonstrated that the short isoform of MX2, which lacks antiviral activity by itself ([@bib25], [@bib34]), is able to bind to the HIV-1 capsid lattice ([Figure 1](#fig1){ref-type="fig"}D), we next asked whether it might play a role in modulating the antiviral function of full-length MX2. Since both isoforms of MX2 are IFN inducible, we tested the ability of the short isoform to inhibit HIV-1 infection when ectopically expressed in the absence of IFNα or in its presence (i.e., when both endogenous isoforms are expressed). As controls, we also ectopically expressed wild-type MX2 (i.e., both isoforms) or an irrelevant protein (luciferase; negative control).

In luciferase-expressing cells, the addition of IFNα yielded the expected drop (∼16-fold) in viral infection ([Figure 3](#fig3){ref-type="fig"}A). As a positive control, overexpression of MX2 severely reduced viral infectivity in both the presence and the absence of IFNα compared to the luciferase-expressing cells. As previously established, expression of the short isoform of MX2 alone had no effect on the efficiency of infection. In contrast, however, this protein significantly diminished the inhibitory effect of IFNα: ∼6-fold inhibition, compared to ∼16-fold for the luciferase control ([Figure 3](#fig3){ref-type="fig"}A). Critically, this result suggests that the short isoform of MX2 can counteract the IFN-induced suppression of HIV-1, with one natural possibility being that it interferes with the activity of the long MX2 isoform. Such interference could be due to two main effects: (1) the short isoform competes with the long isoform for CA binding, or (2) overexpression of the short isoform alters the oligomerization equilibrium between the two MX2 isoforms, thereby perturbing antiviral activity. To distinguish between these scenarios, we overexpressed monomeric MX2 Δ1-25 bearing the M574D mutation ([@bib7], [@bib14]), excluding any possibility of interaction between both protein isoforms. Critically, the IFN-imposed block was reduced to a similar extent as seen with MX2 Δ1-25, indicating that competing for CA binding rather than altered oligomerization underlies the interference with MX2 activity.Figure 3The Short Isoform of MX2 Is a Dominant Negative Regulator of the Long Isoform in HIV-1-Infected Cells(A) U87-MG CD4/CXCR4 cells were transduced with EasiLV-expressing luciferase (Luc), MX2, MX2 Δ1-25, or MX2 Δ1-25 M574D and treated with doxycycline for 24 h. At that time, half of the cells were treated with 500 U/ml IFNα for a further 24 h while the other half was left untreated. Cells were then challenged with an HIV-1-based lentiviral vector expressing GFP. After 2 days, the percentage of GFP-expressing cells was evaluated by flow cytometry (n ≥ 3, mean ± SD). The fold-difference in infection in the presence of IFNα is indicated (^∗^p \< 0.05, unpaired t test). See also [Figure S1](#mmc1){ref-type="supplementary-material"}.(B and C) As in (A), but using CTR CRISPR (B) or MX2 CRISPR (C) U87-MG CD4/CXCR4 cells (n ≥ 3, mean ± SD). The fold-difference in infection in the presence of IFNα is indicated (^∗^p \< 0.05; ns, non-significant; unpaired t test).See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

To further characterize the inhibition of the IFN-imposed block induced by the short isoform of MX2, we used an engineered U87-MG CD4/CXCR4-derived cell line where the MX2 alleles had been inactivated using CRISPR-Cas9 technology ([@bib15]), as well as a control (CTR) CRISPR cell line. Importantly, the reductions in IFN-induced virus suppression seen when MX2 Δ1-25 or MX2 Δ1-25 M574D are expressed were only observed in the CTR CRISPR cells and not in MX2 CRISPR cells, demonstrating that the endogenous MX2 protein is the specific molecular target of this effect ([Figures 3](#fig3){ref-type="fig"}B and 3C; [Figure S1](#mmc1){ref-type="supplementary-material"} shows the corresponding immunoblot analyses of protein expression level).

The G-domain-Capsid Interaction Enhances the Antiviral Activity of MX2 {#sec2.5}
----------------------------------------------------------------------

In seeking to substantiate our model for MX2 isoforms competing for capsid binding, we first returned to the CANC interaction assay. More specifically, we used a competition assay to focus on whether the G domain of MX2 affects binding to CANC complexes in the context of mixed reactions where full-length wild-type MX2 was also present. We therefore incubated CANCs with extracts containing full-length MX2 bearing an HA (hemagglutinin)-tag, plus either wild-type MX2, MX2 R11-13A, MX2 (G~MX1~), or MX1 (NTD~MX2~), each carrying a FLAG-tag. Levels of pelleted MX2-HA and FLAG-tagged proteins were compared to measure how well each MX variant competes against wild-type MX2 for CANC binding; MX2-FLAG served as the control reaction, and all values for relative binding were compared to this sample. As shown in [Figure 4](#fig4){ref-type="fig"}A, MX proteins that interact with capsid via a single region---either the G domain (MX2 R11-13A) or the NTD (MX2 (G~MX1~) and MX1 (NTD~MX2~)---all competed for CANC binding less effectively than wild-type MX2, with relative binding only reaching ∼50%--60% of that of the wild-type protein. Importantly, these reductions in binding capacity were similar in degree irrespective of whether the NTD or the G domain was missing, highlighting the significant role played by both domains in maximizing efficient capsid binding.Figure 4The G Domain of MX2 Enhances the Interaction with CANC Complexes and HIV-1 Inhibition(A) Cell lysates from 293T cells expressing HA-tagged wild-type MX2 were mixed with cell lysates expressing FLAG-tagged wild-type MX2, MX2 R11-13A, MX2 (G~MX1~), or MX1 (NTD~MX2~). These were added to CANC assemblies, pelleted through a sucrose cushion, and the HA- and FLAG-tagged proteins present in input, Sup, and pellet fractions were quantified by immunoblot and corrected for the amount of protein present in the input. The level of bound protein in each competition experiment was normalized to the value obtained in the MX2-HA versus MX2-FLAG sample (n = 3, mean ± SD; ^∗^p \< 0.05; ns, non-significant; unpaired t test).(B) U87-MG CD4/CXCR4 cells were transduced with a lentiviral vector system conferring puromycinR and expressing FLAG-tagged MX1, MX2, or MX2 (G~MX1~) alone or together with the EasiLV-expressing HA-tagged MX2 Δ1-25. Two days later, transduced cells were selected with 1 μg/ml puromycin for 48 h and MX2 Δ1-25 induced with 0.5 μg/ml doxycycline. Cells were then infected with HIV-1~NL4-3~ (185 ng p24^Gag^), and culture supernatants were harvested and stored every 24 h. Infectivity of each collected sample was determined using HeLa-TZMbl indicator cells and measuring chemiluminescent β-galactosidase activity at 48 h (n = 4, mean ± SD). See also [Figures S2](#mmc1){ref-type="supplementary-material"}A and [S3](#mmc1){ref-type="supplementary-material"}.(C) As in (B), but expressing HA-tagged monomeric mutant MX2 Δ1-25 M574D together with MX1, MX2, or MX2 (G~MX1~), instead of MX2 Δ1-25 (n = 4, mean ± SD).See also [Figures S2](#mmc1){ref-type="supplementary-material"}B and [S3](#mmc1){ref-type="supplementary-material"}.

Though these results demonstrate the increased capsid association of wild-type MX2 compared to MX2 (G~MX1~), we have previously reported that this chimeric protein is as antiviral as wild-type MX2 in single-cycle infection experiments ([@bib25]). To gain further insight into this issue, we performed spreading HIV-1 infection experiments in the presence of MX2, MX2 (G~MX1~), or MX1 (as negative control) alone or together with the short isoform of MX2. When alone, MX2 and MX2 (G~MX1~) sustained the same viral replication kinetics, at least during the first 3 days of infection, followed by a slightly lower viral production for MX2 ([Figure 4](#fig4){ref-type="fig"}B, left panel), consistent with previous results ([@bib25]). Importantly, when co-expressed with MX2 (Δ1-25), MX2 displayed stronger antiviral function than MX2 (G~MX1~) ([Figure 4](#fig4){ref-type="fig"}B, right panel), thus confirming the impaired antiviral capacity of MX2 containing the G domain of MX1. In an independent validation, a similar phenotype was also observed in single-cycle experiments where cells were challenged with an HIV-1-based lentiviral vector ([Figure S2](#mmc1){ref-type="supplementary-material"}A). Corresponding immunoblot analyses of protein expression levels are shown in [Figure S3](#mmc1){ref-type="supplementary-material"}A.

We and others have demonstrated the importance of MX2 oligomerization for antiviral activity ([@bib7], [@bib14], [@bib2]). To rule out a role for oligomerization in these results, we performed the same competition experiments described in [Figure 4](#fig4){ref-type="fig"}B in the presence of the monomeric short isoform MX2 Δ1-25 M574D. Results obtained show how under these conditions, where no interaction between the short isoform and wild-type/chimeric MX2 is possible, wild-type MX2 again restricted HIV-1 more effectively than MX2 (G~MX1~) ([Figure 4](#fig4){ref-type="fig"}C; [Figure S3](#mmc1){ref-type="supplementary-material"}B shows the corresponding immunoblot analyses). A similar phenotype was also obtained in single-cycle experiments using an HIV-1 lentiviral vector ([Figure S2](#mmc1){ref-type="supplementary-material"}B).

The Interaction between the G Domain of MX2 and the Capsid Is Complex {#sec2.6}
---------------------------------------------------------------------

In order to map the region(s) of the G domain important for the interaction with capsid, we created three chimeric MX2 ΔNTD proteins where G-domain residues 92--234, 235--322, and 323--387 (i.e., spanning the whole G domain) were swapped for their complementary regions from MX1 (MX2 ΔNTD \[92-234~MX1~\], MX2 ΔNTD \[235-322~MX1~\], and MX2 ΔNTD \[323-387~MX1~\], respectively). None of these chimeric proteins were able to bind to CANC assemblies ([Figure 5](#fig5){ref-type="fig"}A), suggesting the involvement of all three regions in the interaction.Figure 5Identification of Single Residues Important for the Capsid-G-Domain Interaction and the Antiviral Function of MX2(A) Chimeric proteins MX2 ΔNTD (92-234~MX1~), MX2 ΔNTD (235-322~MX1~), and MX2 ΔNTD (323-387~MX1~) were expressed in 293T cells and lysates mixed with CANC assemblies, pelleted through a sucrose cushion. input, Sup, and pellet fractions were analyzed by immunoblot (n = 4).(B) Sequence alignment of the G-domain regions of human MX1 (red) and MX2 (blue) showing the consensus sequence between them (black). Underlined are the 13 regions of sequence difference, with the three regions found to be important for CANC binding highlighted and the three key residues shown in bold. See also [Figure S4](#mmc1){ref-type="supplementary-material"}.(C) Residues found on the three different regions of the MX2 G domain important for CANC binding were individually mutated to their MX1 counterparts in a MX2 ΔNTD background and the proteins expressed in 293T cells. Lysates were mixed with CANC assemblies, pelleted through a sucrose cushion, and input, Sup, and pellet fractions were analyzed by immunoblot (n ≥ 3). A representative immunoblot for CANC (α-CA) is shown. See also [Figure S7](#mmc1){ref-type="supplementary-material"}.(D) U87-MG CD4/CXCR4 cells doubly transduced with puromycinR lentiviral vectors expressing MX2, MX2 G184S, MX2 N260S, or MX2 Q351E together with EasiLV-expressing MX2 Δ1-25 were selected with 1 μg/ml puromycin and treated with 0.5 μg/ml doxycycline to induce MX2 Δ1-25. Cells were infected with HIV-1~NL4-3~ (350 ng p24^Gag^), and culture supernatants were harvested every 24 h. Levels of infectivity for each sample were determined using HeLa-TZMbl indicator cells (n = 4, mean ± SD).See also [Figure S6](#mmc1){ref-type="supplementary-material"}.

Alignment of the G-domain sequences of MX1 and MX2 shows 13 regions where the amino acid sequences differ ([Figure 5](#fig5){ref-type="fig"}B, underlined residues). We therefore introduced each region individually into MX2 ΔNTD and addressed their CANC-binding ability. Interestingly, we found that three discrete regions are necessary for CANC binding (residues 174--185, 257--266, and 334--352; highlighted in gray in [Figures 5](#fig5){ref-type="fig"}B and [S4](#mmc1){ref-type="supplementary-material"}), while all other mutant proteins maintained their ability to bind ([Figure S5](#mmc1){ref-type="supplementary-material"}). Of note, each of these three regions is located within one of the extended regions analyzed in [Figure 5](#fig5){ref-type="fig"}A.

We then individually mutated all residues within these three regions and found that amino acids G184, N260, and Q351 are necessary for the G domain's interaction with the capsid ([Figure 5](#fig5){ref-type="fig"}C; indicated in bold within each highlighted region in [Figure 5](#fig5){ref-type="fig"}B). Finally, we introduced the G184S, N260S, and Q351E mutations individually or in combination into full-length MX2 and performed competition experiments against MX2 Δ1-25 during spreading HIV-1 replication. Cells expressing wild-type MX2 sustained lower levels of viral replication than seen with any of the mutants, particularly when compared to the triple mutant G184S/N260S/Q351E ([Figure 5](#fig5){ref-type="fig"}D; [Figure S6](#mmc1){ref-type="supplementary-material"} shows the corresponding immunoblot analyses). In the absence of MX2 Δ1-25, none of these mutants supported higher viral replication when compared to wild-type MX2 (data not shown), as expected from prior results obtained under the same conditions with MX2 (G~MX1~) ([Figure S2](#mmc1){ref-type="supplementary-material"}A). These results demonstrate that multiple residues within MX2's G domain contribute to capsid binding and confirm their importance for full antivirus function.

Oligomerization Increases the Avidity of the MX2-Capsid Interaction {#sec2.7}
-------------------------------------------------------------------

We and others have shown how MX2 dimerization, but not higher-order oligomerization, is required for viral inhibition ([@bib7], [@bib14]), indicating that the monomeric protein lacks antiviral activity. Therefore, we introduced the monomer-only mutations M574D and M527D into MX2 and MX1 (NTD~MX2~), respectively, and examined their ability to bind to assembled CANC complexes ([Figure 6](#fig6){ref-type="fig"}A). In agreement with previous work, dimerization or higher-order oligomerization was not required for CANC interaction ([@bib7]), although the levels of protein recovered in the pellet fraction were visibly reduced. To quantify the contribution of MX2 oligomerization to capsid binding, we then performed *in vitro* competition experiments. We incubated CANC assemblies with FLAG-tagged MX2 M574D together with HA-tagged wild-type MX1, MX2, or MX2 M574D, and the levels of pelleted proteins were quantified. Inspection of the data shows that the binding of MX2 M574D-FLAG to CANCs was most efficient in the absence of competition (i.e., in the presence of MX1-HA). Importantly, the binding of MX2 M574D-FLAG was reduced more effectively in competition with wild-type MX2-HA, compared to competition against MX2 M574D-HA ([Figure 6](#fig6){ref-type="fig"}B; compare left and middle panels). This result demonstrates the importance of protein oligomerization for increasing the avidity of MX2-capsid binding.Figure 6Oligomerization of MX2 Increases the Avidity for Capsid(A) 293T cells were transfected with vectors expressing wild-type MX2 or monomeric mutants MX2 M574D and MX1 (NTD~MX2~) M527D. Lysates were mixed with CANC assemblies, pelleted through a sucrose cushion, and input, Sup, and pellet fractions were analyzed by immunoblot (n ≥ 3). A representative immunoblot for CANC (α-CA) is shown.(B) Cell lysate from 293T cells expressing FLAG-tagged MX2 M574D was mixed with lysates expressing HA-tagged wild-type MX1, MX2, or MX2 M574D. Mixtures were added to CANC assemblies, pelleted through a sucrose cushion, and the HA- and FLAG-tagged proteins present in the input and pellet fractions quantified by immunoblot. The ability of each protein to bind to CANC was calculated as the ratio between the band intensities measured in pellet and input fractions. Finally, their relative CANC binding activity was determined by comparing the values with those obtained for MX2 M574D-FLAG versus MX2 M574D-HA (n = 3, mean ± SD; ^∗^p \< 0.05; unpaired t test).

Discussion {#sec3}
==========

The G domain of MX1 plays an important role in the inhibition of different viruses, such as IAV and THOV ([@bib37], [@bib38]). Similarly, it has recently been described that the GTPase activity of MX2 is necessary for the inhibition of a number of herpesviruses ([@bib11], [@bib41]). However, the role of the G domain of MX2 in the inhibition of HIV-1 has been less clear, particularly as mutant proteins deficient for GTPase enzymatic activity maintain antiviral activity ([@bib24], [@bib29], [@bib34]).

In this work, we revisit the importance of the MX2 G domain for the control of HIV-1 infection. We show how, in addition to the MX2-capsid interaction that is driven by the NTD, MX2 also interacts with the capsid through its G domain. CANC-interaction experiments using chimeric proteins demonstrate that transfer of the G domain of MX2 to MX1 ΔNTD or GFP is sufficient to confer CANC binding ([Figure 2](#fig2){ref-type="fig"}B), thus defining a second point of interaction in addition to that mediated by the MX2 NTD ([Figure 1](#fig1){ref-type="fig"}C). *In vitro* competition experiments further support these findings and demonstrate that the G domain enhances the interaction between MX2 and the HIV-1 capsid lattice, a point that is illustrated by wild-type MX2 outcompeting MX2 (G~MX1~) for binding to HIV-1 CANC complexes ([Figure 4](#fig4){ref-type="fig"}A). While the contributions of G domains to MX-mediated viral suppression are well recognized ([@bib37], [@bib21], [@bib11], [@bib41]), we now present evidence for a G domain also acting through direct binding to a viral substrate, rather than by catalyzing GTP hydrolysis.

Working from this, we have shown that the short isoform of MX2 (MX2 Δ1-25), by virtue of its intact G domain, can therefore interact with the capsid. Though it lacks antiviral function ([@bib24], [@bib29], [@bib20], [@bib34]), this result prompted us to revisit the functionality of MX2 Δ1-25 during the IFN-induced inhibition of HIV-1 infection (when this form is naturally expressed; [@bib24], [@bib29]). Importantly, we found that MX2 Δ1-25 is an effective suppressor of the IFN response ([Figure 3](#fig3){ref-type="fig"}) and that the endogenous MX2 protein is the target for this phenotype, with competition for CA binding being the underpinning mechanism driving this effect. Consistent with the G domain contributing to CA binding, the short isoform of MX2 is a stronger competitor against MX2 (G~MX1~) than against wild-type MX2 ([Figure 4](#fig4){ref-type="fig"}B). These results point to the short isoform of MX2 playing a biological role during virus infection and invoke a scenario where IFN-stimulated cells can limit the activity of full-length MX2. Though the basis for the regulatory circuit is not yet known, we speculate that full-length MX2 exerts deleterious effects on cell function, such as impeded nuclear transport ([@bib30]), that need to be minimized. In this regard, it is interesting that a number of ISGs express shorter protein isoforms that, at least in the case of mitochondrial antiviral-signaling (MAVS) protein, can exert a checkpoint-like function that dampens the activity of their full-length counterparts ([@bib6]).

Structural data highlight the role played by the G domain in the oligomerization of both MX1 and MX2 ([@bib21], [@bib22], [@bib2]). Therefore, it could be argued that different oligomerization kinetics between MX2 Δ1-25 and MX2 or MX2 (G~MX1~) could be affecting the antiviral activity of the proteins. Nevertheless, in infection experiments carried out in the presence of the monomeric variant MX2 Δ1-25 M574D ([@bib7], [@bib14]), where interactions between different MX2 species are prevented, wild-type MX2 still shows a more potent inhibition of HIV-1 than does MX2 (G~MX1~) ([Figure 4](#fig4){ref-type="fig"}C). This finding is in good agreement with results obtained by overexpression of the same monomeric short isoform in the presence of IFNα, pointing to competition for CA binding as the mechanistic basis for downregulation of the full-length protein.

Detailed mapping of G-domain residues involved in capsid binding identified three amino acids as being important: glycine-184, asparagine-260, and glutamine-351 ([Figure 5](#fig5){ref-type="fig"}C). Infection experiments performed in the presence of competing MX2 Δ1-25 showed that the combined triple-mutant G184S/N260S/Q351E has the weakest antiviral phenotype, with each single mutant having effects that scored as intermediate ([Figure 5](#fig5){ref-type="fig"}D). Interestingly, these three residues are located at distance from each other and are positioned within different surfaces of the G domain ([Figure S7](#mmc1){ref-type="supplementary-material"}). The basis for the effects of these mutations on capsid interactions remains to be determined and may involve direct binding and/or conformational changes. Obtaining high-resolution structural information on the complex between MX2 and the HIV-1 capsid lattice will help answer such questions.

Our description of the MX2 G-domain-capsid interaction is concordant with the conclusions of a recent study showing that higher-order MX2 tubular structures expose their G domains toward the outer surface ([@bib2]), possibly allowing interactions with incoming viral capsids. We can envisage a number of benefits for MX2 containing two CA-binding sites. First, improved capsid binding and enhanced antiviral efficacy may be particularly important during the initial phases of an IFN-induced antiviral response, as ISGs have yet to reach optimal expression levels. Second, the MX2 G-domain-capsid interaction allows fine-tuning of full-length MX2 activity by its short isoform, possibly limiting any deleterious effect that the long isoform may have on cellular functions. Third, MX2 interacts with other cellular factors, notably nucleoporins ([@bib15], [@bib30]), as part of the antiviral process; this interaction also requires the NTD of MX2 such that additional CA-binding sites within MX2 may facilitate simultaneous contact with different ligands, a property that is likely amplified by MX2 oligomerization. In sum, we propose that the interaction of the G domain of MX2 with the capsid not only improves HIV-1 recognition, but may also be required for the precise control of antiviral activity.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Goat polyclonal anti-MX2 N17Santa Cruz BiotechnologiesCat\#sc-47197; RRID:[AB_2147726](nif-antibody:AB_2147726){#interref30}Mouse anti-goat-HRP (horse radish peroxidase)Santa Cruz BiotechnologiesCat\#sc-2354; RRID:[AB_628490](nif-antibody:AB_628490){#interref35}Mouse monoclonal anti-Flag-HRP M2SigmaCat\#F3165-1MG; RRID:[AB_259529](nif-antibody:AB_259529){#interref40}Rat monoclonal anti-HA-HRP 3F10SigmaCat\#12 013 819 001; RRID:[AB_390917](nif-antibody:AB_390917){#interref45}Mouse monoclonal anti-CA 24.2[@bib17]N/AMouse monoclonal anti-tubulinSigmaCat\#T5168-.2ML; RRID:[AB_477579](nif-antibody:AB_477579){#interref50}Goat monoclonal anti-mouse IRDye fluorescentLi-Cor BiosciencesCat\#926-32210; RRID:[AB_621842](nif-antibody:AB_621842){#interref55}Rabbit polyclonal anti-MX1AbcamCat\#ab95926; RRID:[AB_10677452](nif-antibody:AB_10677452){#interref60}**Bacterial and Virus Strains**HIV-1~IIIB~[@bib28]N/AHIV-1~NL4.3~[@bib1]N/A*Escherichia coli* Rosetta (DE3)Merck MilliporeCat\#70954**Chemicals, Peptides, and Recombinant Proteins**Isopropyl β-D-1-thiogalactopyranoside (IPTG)ThermoFisher ScientificCat\#R0393Ammonium sulfateSigmaCat\#A4418-1KGPoly(ethyleneimine) solutionFluka AnalyticalCat\#3880-100MLMES hydrateSigmaCat\#M8250-250GDithiothreitol (DTT)ThermoFisher ScientificCat\#20290Sodium chlorideVWR ChemicalsCat\#27810.364Phenylmethanesulfonyl fluorideSigmaCat\#P7626-1GTris BaseFisher ScientificCat\#BP152-5Potassium chlorideSigmaCat\#P9541-1KGSucroseSigmaCat\#S0398-1KGHiTrap SP HP columnsGe Healthcare Life SciencesCat\#17115201cOmplete Mini protease inhibitor cocktail tabletsSigmaCat\#11836153001GlycerolSigmaCat\#G5516-1LDMEM, high glucose, GlutaMAX SupplementThermoFisher ScientificCat\# 10566016Fetal Bovine SerumThermoFisher ScientificCat\#10270Penicillin Streptomycin (Pen Strep)ThermoFisher ScientificCat\#15140-122EcoRI-HFNew England BiolabsCat\#R3101SNotI-HFNew England BiolabsCat\#R3189SXhoINew England BiolabsCat\#R0146LBamHINew England BiolabsCat\#R)136MPuromycinThermoFisher ScientificCat\#A1113802IFNα-2bINTRON A, Merck, Sharpe & Dohme Corp.N/ADoxycyclineSigmaCat\#D9891EDTAInvitrogenCat\#AM92260G**Critical Commercial Assays**HIV-1 p24 antigen ELISA kitPerkinElmerCat\#NEK050001KTTropix Galacto-Star kitThermoFisher ScientificCat\#T1014**Deposited Data**PDB file[@bib19]4WHJ**Experimental Models: Cell Lines**HeLa-TZMblNIH AIDS Reagent ProgramCat\#8129293TATCCCat\#CRL-3216U87-MG CD4/CXCR4[@bib24]N/A**Oligonucleotides**TG50: TGTGTGTGTGTGTGTGTGTGTG\
TGTGTGTGTGTGTGTGTGTGTGTGTGTGThis paperN/A**Recombinant DNA**pST39[@bib45]N/ApCAGGs[@bib25]N/AEasiLV-MCS[@bib24]N/APuromycinR[@bib24]N/A**Software and Algorithms**ImageJ[@bib100]<https://imagej.nih.gov/ij/>GraphPad Prism version 6.0.0GraphPad Software<https://www.graphpad.com>

Lead Contact and Materials Availability {#sec4.2}
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For further information and requests for reagents, please contact the Lead Contact, Michael H. Malim (<michael.malim@kcl.ac.uk>). The plasmids generated in this study are available upon request without restriction.

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Cells {#sec4.3.1}

Control CRISPR U87-MG cells and MX2 CRISPR U87-MG cells have been described before ([@bib15]). The CRISPR modified cells, U87-MG CD4/CXCR4 cells ([@bib24]), HeLa-TZMbl indicator cells (NIH AIDS Reagent Program) and 293T cells were cultured in Dulbecco's modified Eagle medium (DMEM) supplemented with heat-inactivated fetal bovine serum (10%), L-glutamine, penicillin (100 U/ml) and streptomycin (100 μg/ml).

### HIV-1 and lentiviral vector infections {#sec4.3.2}

Wild-type HIV-1~NL4-3~ ([@bib1]) stocks were obtained by filtration of culture medium from transfected 293T cells, and p24^Gag^ content determined by ELISA according to the manufacturer's instructions (Perkin-Elmer). U87-MG CD4/CXCR4 cells were transduced with either puromycinR encoding Flag-tagged MX2, MX1, MX2 (G~MX1~), MX2 G184S, MX2 N260S, MX2 Q351E or MX2 G184S/N260S/Q351E alone, or together with EasiLV encoding HA-tagged MX2 Δ1-25 or MX2 Δ1-25 M574D. After selection for puromycin resistant cells for 48 h, 2.5x10^4^ cells were seeded in a 24 well plate, challenged with HIV-1~NL4-3~ (corresponding to 185 ng p24^Gag^ for experiments comparing MX1, MX2 and MX2 (G~MX1~); or 350 ng p24^Gag^ for experiments comparing wild-type MX2 and mutants) and the medium replaced after 6 h. For every subsequent 24 h period, for a total of 120 h, medium was filtered and stored at −80°C. To quantify released infectious virus at each time point, HeLa-TZMbl indicator cells (NIH AIDS Reagent Program) were challenged and productive infection determined at 48 h by measuring chemiluminescent β-galactosidase activity using the Tropix Galacto-Star system according to the manufacturer's instructions (Applied Biosystems).

HIV-1 based lentiviral particles expressing GFP (HIV-1/GFP) were produced as described previously ([@bib24]). Infectivity experiments using EasiLV and/or puromycinR transduced U87-MG CD4/CXCR4 cultures were carried out as previously described, with the percent of cells expressing GFP enumerated by flow cytometry (FACSCanto II; BD Biosciences) at 48 h post infection ([@bib14]). For experiments where U87-MG CD4/CXCR4 cells were treated with IFNα, cells were transduced with EasiLV vectors expressing either luciferase, MX2, MX2 Δ1-25 or MX2 Δ1-25 M574D and the medium replaced 6 h later for fresh DMEM containing 0.5 μg/ml doxycycline. 24 h later, 500 U/ml of IFNα-2b (INTRON A, Merck, Sharpe & Dohme Corp.) was added, and after a further 24 h the cells were challenged with HIV-1/GFP. After 48 h, productive infection was monitored by flow cytometry.

Method Details {#sec4.4}
--------------

### Protein expression and purification {#sec4.4.1}

DNA encoding HIV-1~IIIB~ ([@bib28]) Capsid-Nucleocapsid (CANC, corresponding to Gag residues 133-432) was PCR amplified and inserted into pST39 ([@bib45]) using the NdeI and BamHI sites. Protein was expressed in *Escherichia coli* Rosetta (DE3) cells (Merck Millipore) as previously described ([@bib40]). Briefly, CANC expression was induced with 1 mM of isopropyl β-D-thiogalactopyranoside (IPTG) for 6 h at 30°C. Cells were collected by centrifugation and lysed by sonication. Cell debris were removed by centrifugation at 30000 g for 20 min. Nucleic acids present in the supernatant were removed by adding of 0.11 volumes of 2 M ammonium sulfate and the same volume of 10% polyethylenimine (PEI) pH 8.0. CANC was precipitated from the supernatant by adding 0.35 volumes of saturated ammonium sulfate and centrifugation at 10000 g for 15 min. Pelleted protein was resuspended in 50 mM MES pH 6.5, 1 mM EDTA, 1 mM DTT, 0.5 M NaCl, 10% glycerol, 1 mM PMSF and then diluted with the same buffer lacking NaCl to a final concentration of 0.2 M NaCl. This was cleared by centrifugation and CANC polished by cation-exchange chromatography on a 5 mL HiTrap SP HP column (GE Healthcare) using 50 mM MES pH 6.5, 1 mM EDTA, 1 mM DTT, 0.2 M NaCl, 10% glycerol, 1 mM PMSF as the equilibration buffer. CANC was eluted following a linear gradient resulting from mixing the equilibration buffer with the same buffer adjusted to 1 M NaCl. Protein-enriched fractions were pooled and CANC was precipitated by adding one volume of saturated ammonium sulfate. Finally, resulting CANC was resuspended at 200 μM in 30 mM MES pH 6, 1 mM EDTA, 0.5 M NaCl, 10 mM DTT, and stored at −80°C.

### *In vitro* assembly of CANC complexes {#sec4.4.2}

Assembled CANC complexes were obtained by diluting the purified protein to 40 μM in 50 mM Tris-HCl pH 8, 100 mM NaCl with 5 μM TG50 oligonucleotide and overnight incubation at room temperature. The sequence of TG50 is: 5′-25(TG)-3′

### CANC pull-down {#sec4.4.3}

293T cells transfected with vectors expressing hemagglutinin (HA)- or Flag-tagged proteins were harvested and resuspended in hypotonic lysis buffer (10 mM Tris-HCl pH 8, 10 mM KCl, 1x protease inhibitor cocktail \[Roche\]) and lysed using a Dounce homogeneizer. Lysates were cleared by centrifugation at 20000 g at 4°C for 15 min. In pull-down experiments, 200 μL of cell lysates were mixed with 40 μL of 40 μM assembled CANC (an input sample was reserved from this mix) or 40 μL of Capsid assembly buffer (Cab, 50 mM Tris-HCl pH 8, 100 mM NaCl) containing 5 μM TG50 and incubated under gently agitation at room temperature for 1 h. In the case of competition experiments, 200 μl of cell lysate expressing HA-tagged proteins and 200 μl of cell lysate expressing Flag-tagged proteins were mixed with 80 μL of 40 μM assembled CANC. The mixture was then overlaid onto a 250 μL sucrose cushion (70% weight/volume) and centrifuged at 20000 g at room temperature for 10 min. A sample of the supernatant was withdrawn for further analysis. The pellet was washed with 500 μL wash buffer (50 mM Tris-HCl pH 8, 50 mM NaCl, 5 mM KCl), and re-centrifuged at 10000 g at room temperature for 8 min. Finally, the pellet was resuspended in 50 μL of 1x SDS-PAGE loading buffer. Input, supernatant and pellet fractions were analyzed by immunoblot using anti-MX2 goat polyclonal antibody (N17, Santa Cruz Biotechnology) and mouse anti-goat horseradish peroxidase (HRP)-conjugated monoclonal antibody (Santa Cruz), anti-Flag HRP-conjugated mouse monoclonal M2 (Sigma), anti-HA HRP-conjugated rat monoclonal antibody (Sigma), anti-CA mouse monoclonal 24.2 ([@bib17]) or anti-tubulin mouse monoclonal (Sigma) together with goat anti-mouse IRDye fluorescent monoclonal antibody (Li-Cor Biosciences) and detected using a LI-COR Odyssey FC imaging system (LI-COR Biosciences).

### Plasmid constructs {#sec4.4.4}

pCAGGs plasmid (Adgene) was used for the expression of cDNA fragments used in transfection experiments, after PCR amplification and inclusion of either Flag- or HA-tags, using EcoRI-XhoI or NotI-XhoI sites. Fragments encoding the chimeric proteins GFP (NTD~MX2~), GFP (G~MX2~), MX2 ΔNTD (92-234~MX1~), MX2 ΔNTD (235-322~MX1~) or MX2 ΔNTD (323-387~MX1~) were produced by standard overlapping PCR. Truncated fragments encoding MX2 ΔNTD, MX1 (NTD~MX2~) or GFP (NTD~MX2~) were obtained from full-length versions ([@bib25]) using PCR. Site-directed mutagenesis was used to obtain single or multiply mutated constructs, using PCR amplification methods. Where required, DNA constructs were cloned into the doxycycline-inducible lentiviral vector EasiLV-MCS ([@bib24]) or into a lentiviral vector expressing a CD4-IRES-puromycin N-acetyltransferase expression cassette (puromycinR) ([@bib24]) using BamHI-XhoI restriction sites.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

All statistical analyses were performed using GraphPad Prism 6.0 (GraphPad Software Inc.). For each experiment, mean ± SD was calculated and the unpaired t test was applied in all cases, considering p \< 0.05 as the level of statistical significance. Corresponding results from statistical analyses performed can be found in the relevant figure legends.

Data And code Availability {#sec4.6}
--------------------------

This study did not generate any unique datasets or code.
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